drugset / Trial / NCT05567770
ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer
Phase 1
Withdrawn
Weill Medical College of Cornell University
Convergent Therapeutics, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of combining Actinium- J591 with radiation therapy or with androgen deprivation therapy.
Timeline
- Start
- 2023-12
- Primary completion
- 2025-01
- Completion
- 2030-01
Outcome
Outcome not reported
Stopped: “Stakeholder elected not to proceed with the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Actinium-J591 | Unknown | — | — |